Stocks To Buy

Q1 2026 was a rough quarter. The S&P 500 dropped 4.33%, Middle East tensions hammered energy prices, AI fears sparked a "SaaS-pocalypse," and private credit markets were rattled enough that most BDCs restricted redemptions. Against that backdrop, Royalty Pharma (NASDAQ: RPRX) gained 25.6%. That kind of divergence doesn't happen by accident. Patient Capital Management, a Baltimore-based value shop, called RPRX its top Q1 contributor in its recently published investor letter. The core of their argument: Royalty Pharma is the world's largest ...
Read More About This

Eric Fry made his name in the early 2000s by doing something that felt crazy at the time: walking away from the hottest tech stocks at the peak of the dot-com boom and buying the boring stuff instead. Hotels. Copper miners. Fashion houses. It worked spectacularly. Now he's running the same play — this time against AI. Fry's thesis, laid out in his Smart Money column this week, isn't that AI is dead. Far from it. His argument is subtler and ...
Read More About This

Here's a strange thing happening in financial markets right now: oil just blew past $100 a barrel, the U.S. is blockading the Strait of Hormuz, and stocks are barely flinching. If that feels counterintuitive, you're reading the market correctly — because it is. U.S. crude futures jumped more than 8% Monday to $104.93 a barrel after President Trump announced a naval blockade of the Strait of Hormuz following the weekend collapse of U.S.-Iran nuclear talks. Brent wasn't far behind, clearing $102 ...
Read More About This

Novo Nordisk (NVO) is up 3.6% today after announcing a $2.6 billion partnership with Aspect Biosystems, and honestly? This could be the real deal—or it could be pharmaceutical theater. Let's break it down. Here's the situation: Novo Nordisk is the company behind Ozempic and Wegovy, those weight-loss drugs everyone's been talking about. They've basically printed money off semaglutide, raking in $25 billion in revenue in 2022 alone. But here's the thing about blockbuster drugs—they eventually hit a ceiling. So the company's ...
Read More About This

Remember Netscape? That scrappy browser company that went public in 1995 with zero revenue and somehow convinced the world it was worth billions? Its stock doubled on day one, and suddenly everyone wanted a piece of the internet revolution. Well, buckle up. Anthropic just made Netscape look like a lemonade stand. Here's the wild part: Anthropic went from a $1 billion annual revenue run rate in January 2025 to $30 billion in just 15 months. But that's not even the crazy part ...
Read More About This

So the market's been acting like a toddler on a sugar rush—one minute it's up, the next it's spiraling because of geopolitical drama. If you've got $10,000 burning a hole in your pocket and you're wondering where to throw it without losing sleep, we asked nine Wall Street heavyweights exactly that. Their answers? Surprisingly diverse, which is either reassuring or terrifying depending on your risk tolerance. The Consensus Play: Mega-Cap Tech (But Cheaper Now) Several pros are eyeing the "Magnificent Seven"—Nvidia, Amazon, ...
Read More About This

Once upon a time, Beyond Meat was worth $14 billion. Today it’s a penny stock fighting to stay listed on Nasdaq. The story of BYND’s fall from grace is one of the cleanest cautionary tales the market has produced in years — and it’s not over yet. The company filed its long-overdue 2025 annual report this week, which satisfied one Nasdaq listing requirement. But it still faces a second hurdle: its share price needs to trade above $1 for an extended ...
Read More About This

Novo Nordisk just handed the obesity drug market a new gear. The Danish pharma giant launched Wegovy HD — a higher-dose 7.2 mg version of its blockbuster weight-loss drug — across more than 70,000 U.S. pharmacies this week. For patients who stalled on the standard 2.4 mg dose, this is a meaningful clinical upgrade. The numbers are striking. In the 72-week STEP UP trial, patients on Wegovy HD lost about 21% of body weight on average when they stayed on treatment ...
Read More About This